Clinical Trial Detail

NCT ID NCT02475382
Title Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)
Recruitment No longer available
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.